These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32043598)

  • 1. Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
    Valeriano JJLS; Carvalho-Silva WHV; Coelho AVC; Moura RR; Arraes LC; Brandão LAC; Crovella S; Guimarães RL
    J Pharm Pharmacol; 2020 May; 72(5):719-727. PubMed ID: 32043598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
    Checa A; Castillo A; Camacho M; Tapia W; Hernandez I; Teran E
    AIDS Res Ther; 2020 Jul; 17(1):47. PubMed ID: 32727488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
    Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs.
    Dalwadi DA; Ozuna L; Harvey BH; Viljoen M; Schetz JA
    Pharmacol Rev; 2018 Jul; 70(3):684-711. PubMed ID: 29945900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors.
    Mollan KR; Pence BW; Xu S; Edwards JK; Mathews WC; O'Cleirigh C; Crane HM; Eaton EF; Collier AC; Weideman AMK; Westreich D; Cole SR; Tierney C; Bengtson AM;
    Am J Epidemiol; 2021 Oct; 190(10):2075-2084. PubMed ID: 33972995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study.
    Jena A; Sachdeva RK; Sharma A; Wanchu A
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(5):318-22. PubMed ID: 19721097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
    Hoffmann CJ; Fielding KL; Charalambous S; Sulkowski MS; Innes C; Thio CL; Chaisson RE; Churchyard GJ; Grant AD
    AIDS; 2008 Jan; 22(1):67-74. PubMed ID: 18090393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher efavirenz plasma levels correlate with development of insomnia.
    Núñez M; González de Requena D; Gallego L; Jiménez-Nácher I; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2001 Dec; 28(4):399-400. PubMed ID: 11707679
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
    Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
    J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.
    de Almeida TB; de Azevedo MCVM; Pinto JFDC; Ferry FRA; da Silva GAR; de Castro IJ; Baker P; Tanuri A; Haas DW; Cardoso CC
    J Antimicrob Chemother; 2018 Sep; 73(9):2460-2467. PubMed ID: 29868865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS.
    Azevedo LN; Ximenes RAA; Monteiro P; Montarroyos UR; Miranda-Filho DB
    Braz J Infect Dis; 2020; 24(1):65-72. PubMed ID: 31835018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
    Popoola TD; Awodele O; Oshikoya KA
    Afr J Med Med Sci; 2016 Jun; 45(2):179-187. PubMed ID: 29465861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.